<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="733">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04503447</url>
  </required_header>
  <id_info>
    <org_study_id>SARSCOV2SEROPREVALENCEITMSTAFF</org_study_id>
    <nct_id>NCT04503447</nct_id>
  </id_info>
  <brief_title>COVID-19 Seroprevalence Study in ITM Staff</brief_title>
  <acronym>CovAb</acronym>
  <official_title>Severe Acute Respiratory Syndrome Coronavirus (CoV) 2 (SARS-CoV-2) Seroprevalence Study in Institute of Tropical Medicine (ITM) Staff</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Tropical Medicine, Belgium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Belgium, the corona virus disease 2019 (COVID-19) epidemic is in the growing phase of its&#xD;
      second wave.&#xD;
&#xD;
      The Belgian crisis cell is balancing between allowing the economy to recover and minimize the&#xD;
      disease spread. To decide which containment measures should be maintained, reinstalled or&#xD;
      suspended, information on what proportion of people has been infected and on possible risk&#xD;
      factors for virus transmission can be helpful.&#xD;
&#xD;
      This study will be conducted on staff members of the ITM. All staff members will be invited&#xD;
      to participate. Participants will be asked to have a blood sample drawn for detections of&#xD;
      antibodies against SARS-CoV-2 (using one of these two commercial assays: Anti-SARS-CoV-2&#xD;
      ELISA (EUROIMMUN) or WANTAI SARS-CoV-2 Ab ELISA (WANTAI SARS-CoV-2 Diagnostics)) and to&#xD;
      complete a questionnaire about their exposure, both within and outside the ITM, to the&#xD;
      SARS-CoV-2, and about their health and symptoms. The primary objective is to estimate the&#xD;
      occurrence rate of anti-SARS-CoV-2 antibodies or seroprevalence in ITM staff. Secondary&#xD;
      objective is to estimate the SARS-CoV-2 seroprevalence in ITM staff member groups, stratified&#xD;
      by variables obtained through the questionnaire, such as age, gender, symptoms, exposure to&#xD;
      COVID-19 patients/samples, comorbidities, adherence to containment measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is observational and will be conducted on ITM staff members. All members will be&#xD;
      invited to participate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Actual">September 9, 2020</completion_date>
  <primary_completion_date type="Actual">September 9, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 seroprevalence ITM staff</measure>
    <time_frame>Sample is drawn once, within 7 days after recruitment</time_frame>
    <description>The proportion of participating ITM staff members with detectable SARS-CoV-2 antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 seroprevalence in ITM staff, stratified by variables</measure>
    <time_frame>Questionnaire is completed once, at recruitment</time_frame>
    <description>SARS-CoV-2 seroprevalence in ITM staff members stratified by variables obtained through the questionnaire, such as age, gender, symptoms, exposure to COVID-19 patients/samples, comorbidities, adherence to containment measures.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Risk or protective factors for SARS-CoV-2 seropositivity</measure>
    <time_frame>Questionnaire is completed once, at recruitment</time_frame>
    <description>To identify factors that are associated with an elevated or reduced risk of seropositivity in ITM staff and the Belgian working population in general.</description>
  </other_outcome>
  <enrollment type="Actual">330</enrollment>
  <condition>Covid19</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Active ITM staff members&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be an active ITM staff member&#xD;
&#xD;
          -  Be willing and able to complete the questionnaire&#xD;
&#xD;
          -  Be willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Doctor of Philosophy (PhD) students, Master students and interns of the ITM&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marjan Van Esbroeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Tropical Medicine, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Tropical Medicine</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>humans</keyword>
  <keyword>COVID-19</keyword>
  <keyword>pandemics</keyword>
  <keyword>SARS virus</keyword>
  <keyword>cross-sectional studies</keyword>
  <keyword>seroepidemiological studies</keyword>
  <keyword>Belgium</keyword>
  <keyword>risk factors</keyword>
  <keyword>seroprevalence</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study population being only ITM staff members, individual participant data (IPD) cannot be shared due to privacy reasons</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

